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It has been long known that incessant tachycardia and severe hypertension can cause
heart failure (HF). In recent years, it has also been recognized that more modest
elevations in either heart rate (HR) or blood pressure (BP), if sustained, can be a risk
factor both for the development of HF and for mortality in patients with established
HF. Heart rate and BP are thus both modiﬁable risk factors in the setting of HF. What
is less clear is the question whether routine systematic monitoring of these simple
physiological parameters to a target value can offer clinical beneﬁts. Measuring
these parameters clinically during patient review is recommended in HF manage-
ment in most HF guidelines, both in the acute and chronic phases of the disease.
More sophisticated systems now allow long-term automatic or remote monitoring of
HR and BP and whether this more detailed patient information can improve clinical
outcomes will require prospective RCTs to evaluate. In addition, analysis of patterns
of both HR and BP variability can give insights into autonomic function, which is also
frequently abnormal in HF. This window into autonomic dysfunction in our HF
patients can also provide further independent prognostic information and may in it-
self be target for future interventional therapies. This article, developed during a
consensus meeting of the Heart Failure Association of the ESC concerning the role of
physiological monitoring in the complex multi-morbid HF patient, highlights the im-
portance of repeated assessment of HR and BP in HF, and reviews gaps in our knowl-
edge and potential future directions.
Introduction
Monitoring heart rate (HR) and blood pressure (BP) is an
established part of routine clinical practice in heart fail-
ure (HF) patients. The role of an elevated HR and BP in
determining cardiovascular risk is well-known since the
Framingham study.1 Hypertension is the most prevalent
risk factor for HF in the developed world, and long
known to be a major and remediable risk factor for HF.
The optimal target for BP control in primary prevention
has been evaluated in many large-scale antihypertensive
trials, but the optimal target BP or HR within an estab-
lished HF population is less clear. The impact of elevated
HRs on adverse outcomes and mortality in HF has been
extensively studied,2,3 especially in sinus rhythm. For HR,
we have compelling evidence that it is beneficial to tar-
get a HR close to 60 b.p.m., but for BP the optimal tar-
get remains unclear.*Corresponding author. Tel: þ39 06 5225 2409, Fax: þ39 06 5225 2465,
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Increased HR has a complex interaction with BP, in the
short-term BP increases cause reflex bradycardia via the
arterial baroflex system and yet the same factors that drive
an increased BPalso frequently drive an increased HR, such
as increased sympathetic tone. The development of sys-
tems to continuously measure both BP and HR can offer
novel ways for us to measure HR and BP behaviour and to
do so in intense detail.4 It may well be that the complex in-
terplay of these control systems of BP and HR and of respi-
ration may offer even more powerful ways to measure
prognostic risk within the HF population5 and devise novel
interventions.6 Much of this HR/BP interaction behaviour is
linked to the complex autonomic nervous system and its re-
flex control systems, which themselves are now being eval-
uated as a therapeutic target in HF.7 It may well be that
measurement of BP and HR by continuous or semi-
continuous monitoring may offer a window for us to use
this new research to improve our care of HF patients8,9 and
also to offer novel targets for intervention in HF. Thus, both
BPand HR, and also their interactions, carry potentially im-
portant clinical value in the management of HF, and may in
future offer us new therapeutic targets and approaches to
managing our HF patients.
Benefits of heart rate and blood pressure
monitoring in heart failure
Monitoring of HR and BP can contribute to improved out-
comes in HF management if it leads to more effective use
of guideline-directed medical therapy. In the case of rest-
ing HR in sinus rhythm, there is an inverse relation between
this parameter and life expectancy.10 Increased resting si-
nus HR is a risk factor for the development of HF and sud-
den cardiac death11,12 and HR reduction a beneficial
predictive factor in HF.13 It has been demonstrated that HR
reduction by 10 beats saves almost 5 kg ATP per day.14 In
fact, chronic HF is characterized by higher energy expendi-
ture and blood supply to the myocardium, with impaired
vascular resistance and ventricular loading and mechanical
dyssynchrony.
The BEAUTIFUL trial showed the prognostic relevance of
HR in HF with reduced ejection fraction patients, showing
that those with higher HR had greater occurrence of car-
diovascular death and HF hospitalization.15 Similarly, the
SHIFT trial found that the risk of cardiovascular death and
HF hospitalization increased by 3% with every beat increase
from baseline HR and by 16% for every 5 b.p.m. increase.16
The CHARM programme17 revealed the prognostic impor-
tance of temporal changes in resting HR in HF. In fact,
change in HR over time predicted the outcome in HF
patients. This further highlights the need for frequent out-
patient monitoring of HR. Indeed, HR is a prognostic factor
in HF especially in the early post-discharge period where it
is related to symptomatic improvement and prognosis.18
The EVEREST trial clarified that elevated 1 and 4-week
post-discharge HR predicted mortality in patients with HF
and left ventricular systolic dysfunction in sinus rhythm.19
Monitoring HR in these post-discharge intervals is, there-
fore, recommended.
Finally, a meta-analysis20 demonstrated that the magni-
tude of HR reduction is associated with the survival benefit
of beta-blockers in HF, whereas the dose of beta-blocker is
not. This implies that HR reduction in beta-blocker treat-
ment for chronic HF mainly contributes to the clinical ben-
efit in this treatment.21,22 In contrast to the case for sinus
rhythm in atrial fibrillation there is no clear association be-
tween HR and prognosis at least over the range of HR from
60 to 100 b.p.m.23
As for HR, BP is a key prognostic variable to bemonitored
over time, being directly related to HF development and
progression.1 Chronic hypertension has the potential to de-
termine structural cardiac changes and ventricular dys-
function. For this reason, the lifetime risk for HF doubles in
those with BP >160/100 vs. <140/90mmHg in both
sexes.24 Further, there is increased recognition of the
harmful consequences of pre-hypertensive chronic states
(<140mmHg).25 There is no clear cut-off point delimitat-
ing the need for antihypertensive therapy, as the associa-
tion between systolic BP and HF risk is continuous.25,26
More complex BP behaviour may also be important tomoni-
tor in HF syndromes such as the interaction of BP and HR
variability (HRV) discussed elsewhere in this article and BP
response to simple tests.27
Guidelines-based indications for in-hospital
heart rate and blood pressure monitoring
According to the ESC guidelines,28 standard non-invasive
monitoring of HR and BP is recommended (Class I) and
should be performed from the initial presentation of HF.
For in-hospital monitoring, the 2018 guidance from the
HFA/ESC29 indicated that assessments of HR and BP should
be repeated at intervals. The first monitoring should occur
during hospitalization for acute HF, in order to provide opti-
mal management and vaso-active drug usage.30,31
Baseline/initial monitoring usually is performed in the
emergency department at the point of initial admission.
From then on clinical status monitoring should be per-
formed based on the changing clinical variables of the pa-
tient. This usually happens in intensive or critical care unit
settings. Repeated monitoring of HR and BP is made in the
general ward or prior to discharge.29 Finally, serial assess-
ments of HR and BP should be part of a multidisciplinary
after-discharge patient monitoring programme (remote
monitoring).
Remote patient monitoring: implantable
devices
Using implantable devices, HR and BP can be easily moni-
tored over time, in order to prevent decompensation and
consequent rehospitalizations.4,32–34 Often, before an epi-
sode of decompensation, a rapid increase in mean HR
occurs, and it can be simply detected by an implantable
device. Measurement of short-term HRV can similarly pre-
vent sudden cardiac death in chronic HF.29 Among currently
available sensors, HR derivatives are able to assess mean
HR, nocturnal HR, HRV, HRV footprint, and HR during
exercise.
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For BP monitoring, haemodynamic sensors allow the de-
tection of right ventricular pressure (Chronicle IHM),35 RV
dP/dtmax, left atrial pressure (HeartPOD),
36 and pulmonary
artery pressure (Champion).37 There is encouraging evi-
dence showing the effectiveness and safety of implantable
device measurements and their correlation with serial
invasive measurements. Positive results come from meta-
analyses,38–41 whereas few clinical trials to date have dem-
onstrated that implementation of an implantable device
improves patient outcome, a notable exception being the
CardioMEMS device. This represents an important knowl-
edge gap to be fulfilled.
Conclusions
Repeated assessment of HR and BP over time is recom-
mended for the care of patients with HF and provides prog-
nostic information. Serial comprehensive inpatient and
outpatient monitoring is crucial to the optimal manage-
ment of acute and chronic HF patients to improve out-
comes and to prevent adverse events.42–46
However, most of the guideline recommendations re-
lated to monitoring are based on consensus of opinion of
the experts and/or small studies, retrospective studies
and/or registries (level of evidence C).47 For this reason,
additional research is warranted.
Conflict of interest: none declared.
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